Exposed: Why SCR7 Helps Make All Of Us Much Happier
, Ridgefield, CT, United States, 5Centro M��dico Dra. De Salvo, Fundaci��n Respirar, Buenos Aires, Argentina, 6NUPAIVA (Asthma Research Centre), Universidade Federal De Santa Catarina, Santa Catarina, Brazil, 7Boehringer Ingelheim Pty Limited, Sydney, Australia, 8Department of Thoracic Medicine, Concord Hospital Background:?The novel LABA olodaterol (O) has 24-h bronchodilator activity. Objective:?To evaluate the symptomatic benefit of O QD in patients (pts) with GOLD 2�C4 COPD. Methods:?In replicate, randomized, double-blind, placebo (P)-controlled, parallel-group studies, pts with post-bronchodilator FEV1?Roxadustat via Respimat?, formoterol (F; 12?��g) BID via Aerolizer? or P for 48 weeks (wks; Study A: NCT00793624; PTPRJ Study B: NCT00796653). Pts continued to receive usual care background COPD maintenance therapy, including SAMA, LAMA, ICS and xanthines. In addition to FEV1-based primary end points, TDI and SGRQ after 24?wks were identified as co-primary and key secondary symptomatic end points, respectively. Results:?904 (Study A) and 934 (Study B) pts were treated. In the primary analysis using a mixed model for repeated measures (MMRM; combined dataset), there was no significant difference in TDI focal score after 24?wks for O or F vs P. A post hoc analysis using pattern mixture modelling (PMM) to account for discontinued pts demonstrated statistical significance for O vs P. There were significant improvements in SGRQ total score with O, but not F, vs P after 24?wks using MMRM and PMM. Adjusted mean difference vs P after 24?wks (combined dataset) TDI focal score SGRQ total score MMRM PMM MMRM PMM *p?=?ns; Conclusions:?Lung function improvements with O QD translated into symptomatic benefit in COPD pts receiving usual care background therapy. Funding:?Boehringer Ingelheim. BASHAM J1, YONG T1, CAMPBELL D1,2, BARDIN P1,2, FINLAY P1,2, GUY P1, LEONG P1, CHAZAN A1 1Monash Health, 2Monash University Aim:?Dietary nitrate has been demonstrated to have beneficial vascular effects1 and enhance performance in healthy individuals and elite athletes. The aim of this study is to investigate whether dietary nitrate administered as beetroot SCR7 cell line juice can enhance exercise capacity in subjects with COPD and if it is a safe dietary supplement for this population. Method:?19 patients with COPD had lung function testing, incremental shuttle walk test and endurance shuttle walk test to assess exercise capacity. Patients also completed a safety phase; postural blood pressure, heart rate and symptoms were recorded periodically up to 4 hours post consumption of beetroot juice. Results:?19 subjects have completed the safety phase. An insignificant change in systolic pressure was observed at post consumption of the beetroot juice (mean decrease 5.03?mmHg; maximum 30?mmHg).
